Search Results - "Susca, Sara"

"Superresponders" at biologic treatment for psoriasis: A comparative study among IL17 and IL23 inhibitors.

Authors: Mastorino, Luca Susca, Sara Cariti, Caterina et al.

Source: Experimental Dermatology. Dec2023, Vol. 32 Issue 12, p2187-2188. 2p.

Tildrakizumab in real‐life shows good efficacy in moderate‐to‐severe psoriasis regardless of previous use of biologic drugs and joint involvement.

Authors: Mastorino, Luca Cariti, Caterina Susca, Sara et al.

Source: Dermatologic Therapy. Nov2022, Vol. 35 Issue 11, p1-3. 3p.

Risankizumab shows high efficacy and maintenance in improvement of response until week 52.

Authors: Mastorino, Luca Susca, Sara Megna, Matteo et al.

Source: Dermatologic Therapy. May2022, Vol. 35 Issue 5, p1-10. 10p.

Comparison between brodalumab, secukinumab and ixekizumab effectiveness and drug survival: A real‐life experience on 638 patients with psoriasis.

Authors: Mastorino, Luca Cariti, Caterina Susca, Sara et al.

Source: Experimental Dermatology. Sep2023, Vol. 32 Issue 9, p1591-1594. 4p.

Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.

Authors: Roccuzzo, Gabriele Mastorino, Luca Susca, Sara et al.

Source: Clinical & Experimental Dermatology. Apr2023, Vol. 48 Issue 4, p379-381. 3p. 1 Chart.

Effectiveness of Brodalumab on Scalp, Palmoplantar, and Genital Psoriasis: A Descriptive Pilot Study.

Authors: Mastorino, Luca Celoria, Valentina Macagno, Nicole et al.

Source: Dermatologic Therapy. 10/26/2023, p1-5. 5p.

Characterization of a Commercial, Front-Illuminated Interline Transfer CCD Camera for use as a Guide Camera on a Balloon-Borne Telescope.

Authors: Clark, Paul Massey, Richard Chang, Herrick L. et al.

Source: Journal of Astronomical Instrumentation. Nov2014, Vol. 3 Issue 2, p-1. 14p.

Drug survival und klinische Wirksamkeit von Secukinumab, Ixekizumab, Brodalumab, Guselkumab, Risankizumab und Tildrakizumab in der Behandlung der Psoriasis: Drug survival and clinical effectiveness of secukinumab, ixekizumab, brodalumab, guselkumab, risankizumab, tildrakizumab for psoriasis treatment

Authors: Mastorino, Luca Dapavo, Paolo Susca, Sara et al.

Source: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology: JDDG Jan2024; Vol. 22 (1).

Journal Info: Publisher: Wiley-Blackwell ISSN: 1610-0379